论文部分内容阅读
用银染PCR－SSCP方法检测61例不同类型的白血病P53抗癌基因点突变，结果在26例淋巴细胞白血病中检测出2例有P53基因的点突变，在35例髓系白血病中检测出1例有P53基因的点突变。临床观察3例P53基因点突变患者对化疗药物不敏感，其中2例病程进展凶险。结果显示，P53抗癌基因点突变导致功能失活在白血病发病过程中起一定的作用，并可作为判断预后和化疗反应性的检测指标。
The point mutations of P53 anti-oncogenes in 61 cases of different types of leukemia were detected by silver-stained PCR-SSCP method. Two of the 26 cases of point mutations with P53 were detected in lymphocytic leukemia and detected in 35 cases of myeloid leukemia. There are point mutations in the P53 gene. Clinical observation of 3 cases of point mutations in patients with P53 gene is not sensitive to chemotherapy drugs, of which 2 cases of dangerous progress. The results showed that P53 anti-oncogene point mutations leading to functional inactivation play a certain role in the pathogenesis of leukemia, and can be used as a detection index to determine the prognosis and chemotherapy response.